Programmed cell death ligand 1 expression in a case of poorly differentiated lymphocyte-rich hepatocellular carcinoma

Ginji Omori; Takahiro Osuga; Koji Miyanishi; Kota Hamaguchi; Shingo Tanaka; Hiroyuki Ohnuma; Kazuyuki Murase; Kohichi Takada; Minoru Nagayama; Yasutoshi Kimura; Ichiro Takemasa; Yasuhiro Kikuchi; Toshihiko Torigoe; Junji Kato

doi:10.1002/ccr3.4764

Programmed cell death ligand 1 expression in a case of poorly differentiated lymphocyte-rich hepatocellular carcinoma

Clin Case Rep. 2021 Sep 9;9(9):e04764. doi: 10.1002/ccr3.4764. eCollection 2021 Sep.

Authors

Affiliations

¹ Department of Medical Oncology Sapporo Medical University School of Medicine Sapporo Japan.
² Department of Infection Control and Laboratory Medicine Sapporo Medical University School of Medicine Sapporo Japan.
³ Department of Surgery, Surgical Oncology and Science Sapporo Medical University School of Medicine Sapporo Japan.
⁴ Department of Pathology Sapporo Medical University School of Medicine Sapporo Japan.

Abstract

Our pathological study of a case of poorly differentiated lymphocyte-rich hepatocellular carcinoma suggested that immune checkpoint inhibitor may be an effective therapy. The histological type is an important factor in determining treatment choices.

Keywords: hepatocellular carcinoma; immune checkpoint inhibitors; lymphocyte‐rich; lymphoepithelial hepatocellular carcinoma; programmed cell death ligand 1.

Publication types

Case Reports